Breast Cancer Coverage from Every Angle

Komal Jhaveri, MD, on Clinical Implications of New Data on Neratinib, Fulvestrant, and Trastuzumab for TNBC

Posted: Wednesday, February 2, 2022

Komal Jhaveri, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest update from the SUMMIT trial and offers some clinical pearls on the rationale and findings of the study. The data showed that regimens combining neratinib, fulvestrant, and trastuzumab, as well as neratinib and trastuzumab, may benefit patients with hormone–receptor positive, HER2-mutated metastatic breast cancer and HER2-mutated triple-negative disease.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.